A retrospective analysis of elderly population with metastatic colorectal cancer treated with raltitrexed in the target therapy era
| Autor: | Jesus Rodriguez-Pascual, Lucia Ceniceros, Lisardo Ugidos, Enrique Sanz, Antonio Cubillo, César Muñoz, Rafael Alvarez-Gallego |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Cancer Research Chemotherapy medicine.medical_specialty business.industry Colorectal cancer medicine.medical_treatment medicine.disease Clinical trial chemistry.chemical_compound chemistry Elderly population Internal medicine Antifolate Retrospective analysis Medicine Target therapy business Raltitrexed medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 37:e23022-e23022 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | e23022 Background: Raltitrexed is a antifolate chemotherapy agent with activity against metastatic colorectal cancer (mCRC). Most clinical trials with raltitrexed were performed before approval of anti-EGFR and anti-VEGF therapies. Its toxity profile suggests that might be a useful drug to treat elder patients, but there are no specific data in this population group. Methods: A retrospective review of elderly patients (70 years or older) with mCRC treated with raltitrexed monotherapy in our hospital between 2008 and 2017 was conducted. All of them had received previously oxaliplatin, irinotecan, fluoropyrimidines, and bevacizumab as standard therapy. All RAS native patients had received also anti-EGFR drugs. Results: Eighteen elder patients were reviewed, 11 (61%) male. Age ranged 70-85 years (median 78). All patients had ECOG PS 0 or 1. Locations were rectum (4), right colon (8), and left colon (6). Number of treatment lines ranged 2-5 (median 3). Three pts (16%) had received regorafenib previously. KRAS and BRAF were mutated in 61% and 5% respectively. Median number of cycles was 3 (1-13). Response rate was 11% (2 partial responses). Stable disease was achieved in 33%. Median progression-free and global survival were 2.8 (95% CI 1.2-10) and 5.9 (95% CI 1.6-18) months respectively. Grade 3-4 hematologic and non-hematologic toxicities were present in 22% and 5.5% respectively. Dose reduction was needed only in 11%. Sex, location, RAS status were not related to response or survival. Conclusions: Raltitrexed is a well tolerated option por elderly patients after standard treatment of mCRC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|